Filing Details
- Accession Number:
- 0001209191-23-034792
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-06-06 17:07:01
- Reporting Period:
- 2023-06-02
- Accepted Time:
- 2023-06-06 17:07:01
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1802768 | Royalty Pharma Plc | RPRX | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1814899 | W. George Lloyd | C/O Royalty Pharma Plc 110 East 59Th Street New York NY 10022 | Evp, Investments & Clo | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Class A Ordinary Shares | Disposition | 2023-06-02 | 92,221 | $33.65 | 120,000 | No | 4 | S | Indirect | By GWL 2014 G, LLC |
Class A Ordinary Shares | Disposition | 2023-06-02 | 1,686 | $33.54 | 128,314 | No | 4 | S | Indirect | By GWL 2020 G, LLC |
Class A Ordinary Shares | Disposition | 2023-06-05 | 19,215 | $33.54 | 109,099 | No | 4 | S | Indirect | By GWL 2020 G, LLC |
Class A Ordinary Shares | Disposition | 2023-06-06 | 79,099 | $33.82 | 30,000 | No | 4 | S | Indirect | By GWL 2020 G, LLC |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Indirect | By GWL 2014 G, LLC |
No | 4 | S | Indirect | By GWL 2020 G, LLC |
No | 4 | S | Indirect | By GWL 2020 G, LLC |
No | 4 | S | Indirect | By GWL 2020 G, LLC |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Class A Ordinary Shares | 495,860 | Indirect | By GWL 2013 NG, LLC |
Class A Ordinary Shares | 273,960 | Indirect | By IRA |
Class A Ordinary Shares | 3,000 | Direct | |
Class A Ordinary Shares | 4,011 | Indirect | By Spouse |
Footnotes
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.51 to $33.80 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.53 to $33.55 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.50 to $33.69 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.50 to $34.02 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.